Sucampo Pharma Americas
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Sucampo Pharma Americas sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Sucampo Pharma Americas: 14 sponsored US clinical trials, none currently recruiting.
Sucampo Pharma Americas sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 10 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Constipation - Functional, with 1 trials.
Top-decile sponsor footprint
Sucampo Pharma Americas ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
14 total, page 1 of 1
Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
NCT03097861
Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers
NCT03010631
Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation
NCT02766777
Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy
NCT02542215
Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome
NCT02544152
Lubiprostone for Children With Constipation
NCT02138136
Lubiprostone in Children With Functional Constipation
NCT02042183
Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)
NCT01298219
Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
NCT00737594
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
NCT00620061
Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
NCT00597818
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone
NCT00597428
Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone
NCT00595946
Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation
NCT00452335
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 3 | 9 |
| Phase 4 | 1 |
Therapeutic Areas
How the Sucampo Pharma Americas archive is shaped
14 indexed studies, none listed as recruiting (0% open); 11 completed (79%).
Phase mix: 10 late (III/IV) vs 4 early (I/II) (later-stage heavy).
Top condition: Constipation - Functional (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Sucampo Pharma Americas: archived-pipeline peers nationwide
Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Sucampo Pharma Americas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 archived trials
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Sucampo Pharma Americas page
14 registered trials is a research-attention snapshot, not an endorsement of Sucampo Pharma Americas or any single study.
- None of Sucampo Pharma Americas's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Constipation - Functional is the condition Sucampo Pharma Americas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Constipation - Functional trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sucampo Pharma Americas pipeline card: 14 registered trials from official public datasets.Report a data error.